Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer

AstraZeneca

AstraZeneca AB

AstraZeneca trial registry — 249 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
EMA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
249
Drugs
238
Patents
2
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

AstraZeneca clinical trials

Registry index of 249 ClinicalTrials.gov studies linked to AstraZeneca programs — each row shows trial ID, program name, phase, status, and indication.

AstraZeneca trial registry — 249 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for AstraZeneca.

  1. IRIS, D3466C00001 — Phase 3

    Clinical update

  2. D8530C00001 — Phase 1

    Clinical update

  3. D5180C00016 — Phase 3

    Clinical update

  4. D5162C00048 — Phase 2

    Clinical update

  5. D5084C00016 — Phase 1

    Clinical update

  6. GEMCITABINE for Patients with histologically or… — Phase 3

    Clinical update

  7. Datopotamab deruxtecan for Stage I-III Triple-negative Bre… — Phase 3

    Clinical update

  8. D9723C00002 — Phase 1

    Clinical update

Trial registry

249 studies
  1. 2022-500860-36-00

    D5160C00048

    Phase 3 active small_molecule

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    CTIS ↗
  2. 2022-501353-37-00

    D9604C00001

    Phase 3 active small_molecule

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    CTIS ↗
  4. 2022-502576-23-00

    D8990C00001

    Phase 1 active other

    Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.

    CTIS ↗
  5. 2022-502606-33-00

    D516AC00001

    Phase 3 active small_molecule

    Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease

    CTIS ↗
  9. 2022-502774-17-00

    AZD7789

    Phase 2 active small_molecule

    Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma, Advanced or Metastatic Non-small Cell Lung Carcinoma, Advanced or Metastatic Solid Tumors

    CTIS ↗
  11. 2022-502984-39-00

    D5180C00016

    Phase 3 active small_molecule

    Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments

    CTIS ↗
  31. 2023-504277-20-00

    CROSSING

    Phase 3 active small_molecule

    Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus

    CTIS ↗
  36. 2023-504949-31-00

    D967YC00001

    Phase 1 active other

    Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)

    CTIS ↗
  38. 2023-504984-17-00

    D8410C00001

    Phase 2 active small_molecule

    Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma

    CTIS ↗
  43. 2023-505077-32-00

    D7632C00001

    Phase 3 active small_molecule

    Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

    CTIS ↗
  50. 2023-505499-32-00

    BaxHTN / D6970C00002

    Phase 3 active small_molecule

    Uncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agents, including a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.

    CTIS ↗
  62. 2023-506054-20-00

    D7025C00001

    Phase 3 active small_molecule

    Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)

    CTIS ↗
  64. 2023-506197-12-00

    PURSUIT

    Phase 2 active small_molecule

    Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, which is a major risk factor for Cardiovascular Disease (CVD), such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.

    CTIS ↗
  70. 2023-506524-82-00

    ADAURA - D5164C00001

    Phase 3 active small_molecule

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    CTIS ↗
  75. 2023-506891-28-00

    D9075C00001

    Phase 3 active small_molecule

    The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC ≥ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.

    CTIS ↗
  81. 2023-507338-26-00

    D910GC00001

    Phase 3 active small_molecule

    Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).

    CTIS ↗
  85. 2023-507640-36-00

    Baxdrostat, Baxdrostat Placebo

    Phase 3 active small_molecule

    Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.

    CTIS ↗
  87. 2023-507689-26-00

    D910DC00001

    Phase 3 active small_molecule

    Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)

    CTIS ↗
  94. 2023-508162-15-00

    D6402C00012

    Phase 3 active small_molecule

    Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death

    CTIS ↗
  95. 2023-508262-15-00

    Rilvegostomig, Rilvegostomig

    Phase 2 active small_molecule

    Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).

    CTIS ↗
  118. 2023-509631-37-00

    D9268C00001

    Phase 3 active small_molecule

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    CTIS ↗
  121. 2023-509883-89-00

    D516NC00001

    Phase 3 active small_molecule

    Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer

    CTIS ↗
  141. 2024-511646-40-00

    D933LC00001

    Phase 2 active small_molecule

    First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.

    CTIS ↗
  142. 2024-511813-39-00

    D7310C00001

    Phase 3 active small_molecule

    Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

    CTIS ↗
  159. 2024-512667-31-00

    D9103C00001

    Phase 3 active small_molecule

    Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation

    CTIS ↗
  161. 2024-512982-15-00

    D0817C00098

    Phase 3 active small_molecule

    BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer

    CTIS ↗
  166. 2024-513399-17-00

    DANUBE/D419BC00001

    Phase 3 active small_molecule

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    CTIS ↗
  186. 2024-516158-22-00

    DS-8201a

    Phase 2 active small_molecule

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    CTIS ↗
  229. 2025-521639-34-00

    D907HC00001

    Phase 1 active small_molecule

    • Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer

    CTIS ↗
  247. 2025-523947-36-00

    D798MC00002

    Phase 2 active small_molecule

    Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.